Stay up to date with the latest developments and advances in HR+/HER2- early breast cancer care with content from key international congresses, expert-to-expert video discussions and breaking news stories.
Factors associated with abemaciclib discontinuation in monarchE identified
medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib...
ctDNA may serve as a marker for late recurrence in high-risk HR-positive breast cancer
medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative ...
Low-risk luminal A breast cancer patients may be able to forgo radiotherapy
medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast c...
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC)
LUMINA efficacy presentation from ASCO 2022, Chicago
Endocrine response assessment in early breast cancer: are we making progress?
Expert discussion with Nadia Harbeck and Stephen Johnston featuring the ADAPT and POETIC trials
Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1
MonarchE efficacy presentation from ESMO Breast Cancer 2022, Berlin
Additional monarchE analyses add support for adjuvant abemaciclib use
medwireNews: Two subgroup analyses from the monarchE study confirm the benefit of supplementing adjuvant endocrine therapy (ET) with th...
Patritumab deruxtecan shows promise for HR-positive, HER2-negative early breast cancer
medwireNews: A single dose of patritumab deruxtecan (HER3-DXd) elicits a “clinically meaningful” response in previously untre...
Recurrence score, ET response may help to de-escalate HR-positive early breast cancer therapy
medwireNews: Using the 21-gene recurrence score (RS) in conjunction with response to preoperative endocrine therapy (ET) could help to ...
